"The future of immunotherapy lies in understanding what drives response and resistance—so we can match each patient with the therapy that offers the greatest potential for cure.”
New Era of Immunotherapies
Identifying the right patient for the right therapy is central to advancing immunotherapy. Not all patients respond the same, and understanding the biological determinants of response and resistance is critical to guiding treatment strategies. Odetiglucan’s unique immune‑activating properties are being studied to strengthen anti‑tumor immunity and enhance the benefit of complementary therapies.
With more than 700 patients and healthy volunteers treated, Odetiglucan has demonstrated a favorable safety profile and consistent biological activity. Our goal is to conduct focused clinical studies that identify the patient populations and combination settings most likely to achieve durable benefit, paving the way for registration studies.
Partnering for Progress
Partnerships with industry, academics and foundations are fundamental to advancing novel combinatorial therapies. By working together, we accelerate the development of innovative treatments that improve the lives of cancer patients around the world.
Our Team